3,476
Participants
Start Date
March 31, 2016
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
High volume PEG split-dose
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Low volume PEG split-dose
Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
High volume PEG non split, day before
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
Low volume PEG non split, same day
Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
Clear liquid diet
Low residue diet
Early colonoscopy (stratified)
"Early appointments: 7:30 AM to 10h30 AM"
Later colonoscopy (stratified)
"Later appointments: 10:30 AM to 4:30 PM."
Forzani & MacPhail Colon Cancer Screening Centre, Calgary
University of Alberta Hospital, Edmonton
St. Paul's Hospital, Vancouver
Health Sciences center and St. Boniface Hospital, Winnipeg
QEII HSC, Halifax
Western University, London
The Ottawa Hospital, Ottawa
CHUM, Montreal
McGill University Health Centre, Montreal
Hôpital St-Sacrement, CHU de Québec-Université Laval, Québec
Collaborators (1)
Pendopharm
INDUSTRY
Alan Barkun
OTHER